Fibroblast growth factor 23 (IPR028304)
Short name: FGF23
Overlapping homologous superfamilies
- Cytokine IL1/FGF (IPR008996)
- Fibroblast growth factor family (IPR002209)
- Fibroblast growth factor 23 (IPR028304)
Fibroblast growth factors (FGFs) [PMID: 2549857, PMID: 3072709] are a family of multifunctional proteins, often referred to as 'promiscuous growth factors' due to their diverse actions on multiple cell types [PMID: 1705486, PMID: 8760337]. FGFs are mitogens, which stimulate growth or differentiation of cells of mesodermal or neuroectodermal origin. The function of FGFs in developmental processes include mesoderm induction, anterior-posterior patterning, limb development, and neural induction and development. In mature tissues, they are involved in diverse processes including keratinocyte organisation and wound healing [PMID: 11276432, PMID: 23000357, PMID: 15689573, PMID: 10441498, PMID: 23108135, PMID: 23016864]. FGF involvement is critical during normal development of both vertebrates and invertebrates, and irregularities in their function leads to a range of developmental defects [PMID: 1649700, PMID: 11746231, PMID: 14745970, PMID: 8978613]. Fibroblast growth factors are heparin-binding proteins and interactions with cell-surface-associated heparan sulfate proteoglycans have been shown to be essential for FGF signal transduction. FGFs have internal pseudo-threefold symmetry (beta-trefoil topology) [PMID: 10830168]. There are currently over 20 different FGF family members that have been identified in mammals, all of which are structurally related signaling molecules [PMID: 8652550, PMID: 11276432]. They exert their effects through four distinct membrane fibroblast growth factor receptors (FGFRs), FGFR1 to FGFR4 [PMID: 7583099], which belong to the tyrosine kinase superfamily. Upon binding to FGF, the receptors dimerize and their intracellular tyrosine kinase domains become active [PMID: 7583099].
This entry represents fibroblast growth factor 23 (FGF23), which is secreted by osteoblasts and osteoclasts [PMID: 22249518]. FGF23 acts on kidneys, where it decreases the expression of NPT2, a sodium-phosphate cotransporter in the proximal tubule [PMID: 21346724]. FGF23 is responsible for phosphate metabolism, decreasing the reabsorption and increasing excretion of phosphate [PMID: 18310961]. FGF23 is involved in the pathogenesis of three hypophosphatemic disorders; oncogenic osteomalacia (OOM), X-linked hypophosphatemia (XLH) and autosomal dominant hypophosphatemic rickets (ADHR). These conditions are characterised by hypophosphatemia, decreased renal phosphate reabsorption, normal or low serum calcitriol concentrations and defective skeletal mineralisation [PMID: 11409890, PMID: 18310961, PMID: 11062477].
- PTHR11486:SF69 (PTHR11486:SF69)